Individualizing Treatment in CML
With multiple very effective options, patients can now be offered different treatment strategies. Drs. Hughes, Saglio, and Rea discuss issues for TKI selection and sequencing.
New Developments in Essential Thrombocythemia and Polycythemia Vera
When and how to treat ET and PV? Drs. Verstovsek and Michaelis discuss new risk stratification, indications for treatment, and novel agents in development.
Recent Developments in Myelofibrosis
New strategies are emerging to improve outcomes in patients with myelofibrosis. Drs. Verstovsek and Yacoub discuss evolving treatment and prognostic models.
Advances in MDS Biology
Innate immune response dysfunction is now recognized as a driving force in MDS pathogenesis. Drs. List and Garcia-Manero discuss implications for diagnosis, monitoring, and future therapies.
Advances in MDS Treatment
What’s in the pipeline for MDS? Drs. List and Garcia-Manero highlight new therapeutic strategies in development.
New Developments in ALL
What is state-of-the-art in ALL? Drs. Pui, Muffly, and Schmiegelow discuss the clinical impact genomics and new treatments.
Future Perspectives in ALL
Can we do better in ALL? Drs. Pui, Muffly, and Schmiegelow consider unmet needs and opportunities for the future in ALL.
New AML Therapies: For Whom and When?
Recent approvals of several novel therapeutic options, including the first targeted therapies, have dramatically changed treatment algorithms for AML. Drs. Stone and Erba consider the impact of new AML agents on treatment selection and sequencing for defined patient subsets.
A Glimpse at the Future of AML
Decades of research into the biology of AML are beginning to pay off – with more clinical advances in the wings. Drs. Stone and Ravandi discuss their expectations for near-term developments in AML.
Emerging Therapies in Multiple Myeloma
What’s in development for MM? Quite a mixed bag! Drs. Lonial and Orlowski give us a snapshot of some promising novel agents.
Evolving Frontline Strategies in Hodgkin Lymphoma
Novel agents have started to move into frontline. Drs. Ansell and Straus consider new developments and implications for patients - now and in the future.
Toward Personalized Therapy for Follicular Lymphoma
Are we ready for a more tailored approach? Drs. Fowler and Federico consider the question in light of recent developments.
Moving Novel Therapies to Frontline for DLBCL
The use of novel therapies in newly diagnosed patients would represent a long-awaited advance in DLBCL. Drs. Fowler and Younes spotlight progress exploring this strategy.
On the Horizon for Mantle Cell Lymphoma
Emerging clinical data are anticipated to redefine standards of care in the near future. Drs. Rule and Rummel consider implications for clinical practice and patient care.
Evolving Approaches in T-Cell Lymphoma
Novel agents are moving into frontline treatment. Drs. Porcu and Horwitz give an update on emerging combination strategies and immunotherapy for these aggressive lymphomas.